Clinical trials: Stroke Assessment
Stroke
An Open Label, Phase 1b, Ascending Dose Study of DM199
This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in healthy volunteers. The study will be consist of two parts: Part A will focus on intravenous dosing and Part B will directly compare…
- Trial name
- NCT02868996
- Testing
- Recombinant human tissue kallikrein
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- DiaMedica Therapeutics Inc
Acute Ischemic Stroke
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
A phase IIb clinical study to evaluate the safety and efficacy of single or multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).
- Trial name
- NCT05198323
- Testing
- LT3001 Drug Product
- Where
- 2 sites in United States, Taiwan
- Volunteers
- 66 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Atrial Fibrillation, AFib
Stroke Feasibility Study
This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage.
- Trial name
- NCT01997905
- Testing
- AtriClip LAA Exclusion Device
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- AtriCure, Inc.
Acute Ischemic Stroke
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical…
- Trial name
- HEMERA-1 (NCT04677777)
- Testing
- PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Prolong Pharmaceuticals
Acute Ischemic Stroke
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.
- Trial name
- KPCXM18 (NCT07279493)
- Testing
- The KPCXM18 injection
- Where
- 23 sites in China
- Volunteers
- 300 people
- Sponsor
- Kunming Pharmaceuticals, Inc.
Ischemic Stroke
Safety, Tolerability and Pharmacokinetics of SP-8203
Phase I study in health volunteers to assess the safety, tolerability and pharmacokinetics of escalating single doses and multiple doses of SP-8203
- Trial name
- NCT01757795
- Testing
- SP-8203
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Atrial Fibrillation, Left Atrial Appendage
Zenith LAA Occlusion System
Demonstrate the safety and performance of the Zenith LAA Occlusion System and procedure to occlude the Left Atrial Appendage (LAA) from the left atrium (LA) using a minimally invasive technique.
- Conditions
- Atrial Fibrillation, Left Atrial Appendage, Stroke
- Trial name
- NCT05951101
- Testing
- Zenith LAA Occlusion System
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 10 people
- Sponsor
- AuriGen Medical Ltd
Ischemic Stroke
Evaluation of the Safety and Performance of Magneto Microcatheter
A prospective, open label single arm feasibility study to evaluate the safety and performance of the Magneto Microcatheter in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.
- Trial name
- NCT04466033
- Testing
- Magneto Microcatheter
- Where
- 3 sites in Hungary, Israel
- Volunteers
- 4 people
- Sponsor
- Magneto Thrombectomy Solutions
Safety, Tolerability
A Phase 1 Study of Y-3 in US Healthy Volunteers.
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetic profiles of Y-3 in healthy adult volunteers in the United States.
- Conditions
- Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
- Trial name
- NCT06770491
- Testing
- Y-3 for injection
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Neurodawn Pharmaceutical Co., Ltd.
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Spasticity
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total…
- Trial name
- LANTIMA (NCT04752774)
- Testing
- Corabotase, Dysport
- Where
- 81 sites in United States, Austria and 12 more
- Volunteers
- 240 people
- Sponsor
- Ipsen
Stroke, Ischemic
Assessing Safety and Performance of the ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke
The ANA catheter system (may also be designated as "ANA system", "ANA 18 -002" or "ANA device") is a distal access catheter designed to assist in neurovascular procedures by facilitating the insertion and guiding of other devices…
- Trial name
- SOLONDA (NCT04095767)
- Testing
- Neurothrombectomy
- Where
- 9 sites in Spain
- Volunteers
- 74 people
- Sponsor
- Anaconda Biomed S.L.
Atrial Fibrillation, Stroke
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.
- Trial name
- NCT00262600
- Testing
- warfarin, Dabigatran dose 1, Dabigatran dose 2
- Where
- 984 sites in United States, Argentina and 42 more
- Volunteers
- 18,113 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Study to Assess PK, Safety and Tolerability in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.
- Trial name
- NCT06380699
- Testing
- QHRD106 Injection, Human Urinary Kallidinogenase
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Acute Ischemic Stroke
Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)
A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke
- Trial name
- NCT06040476
- Testing
- hUCB
- Volunteers
- 39 people
- Sponsor
- StemCyte, Inc.
Arterial Ischemic Stroke
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
The primary study objective is to assess the safety of afamelanotide while the secondary objective is to assess whether the therapy affects the size of the penumbra, by increasing blood flow, restoring oxygen supply to the brain…
- Trial name
- NCT04962503
- Testing
- Afamelanotide
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Safety and Efficacy of CG-BM1 in Ischemic Stroke
1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Ischemic Stroke. 2. To observe the preliminary effectiveness of CG-BM1 in treating Ischemic Stroke patients.
- Trial name
- NCT07896941
- Testing
- single infusion, 1.0 × 10^6 cells/kg, single infusion, 2.0 × 10^6 cells/kg, single infusion, 3.0 × 10^6 cells/kg
- Where
- China
- Volunteers
- 87 people
- Sponsor
- GuangZhou Cellgenes Biotechnology Co., Ltd.
Heart Failure, Coronary Artery Disease
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and…
- Trial name
- COMMANDER HF (NCT01877915)
- Testing
- Rivaroxaban, Standard of care for heart failure and coronary artery disease
- Where
- 562 sites in United States, Argentina and 30 more
- Volunteers
- 5,081 people
- Sponsor
- Janssen Research & Development, LLC
Ischemic Stroke
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke
The purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.
- Trial name
- NCT01297413
- Testing
- Allogeneic adult mesenchymal bone marrow stem cells
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Stemedica Cell Technologies, Inc.